| Phase 12 trials |
|
Phase 1
|
NCT06551233 |
Apr → Nov 2024 overdue |
urinary bladder cancer |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05773937 |
Jun 2022 → Dec 2024 overdue |
cancer |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT07615660 |
May 2026 → Apr 2029 expected |
neoplastic disease or syndrome |
Convalife (Shanghai) Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06926998 |
Apr 2025 → May 2027 expected |
female reproductive organ cancer |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06947226 |
Apr 2025 → Apr 2026 overdue |
cancer |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06079112 |
Sep 2023 → Dec 2026 expected |
urothelial carcinoma |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07412171 |
Feb 2026 → Dec 2028 expected |
renal pelvis/ureter urothelial carcinoma |
Peking University Third Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07045311 |
Sep 2025 → Mar 2028 expected |
triple-negative breast carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07314723 |
Aug 2025 → Dec 2027 expected |
urothelial carcinoma |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06649331 |
Oct 2024 → Sep 2026 expected |
triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06492005 |
Jul 2024 → Jul 2026 overdue |
triple-negative breast carcinoma |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05582499 |
Nov 2022 → Dec 2027 expected |
HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07556848 |
May 2026 → Dec 2027 expected |
triple-negative breast carcinoma |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06592326 |
Aug 2024 → Sep 2027 expected |
urothelial carcinoma |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|